IGF-1 DES
Compelling concept with clear mechanistic rationale, but research remains confined to laboratory models. Six studies provide solid biochemical understanding but zero human data limits practical applications.
Primarily studied by muscle biology researchers investigating hyperplasia mechanisms and tissue engineering labs working on localized growth factor delivery systems.
Since Feb 2026
6 total
What is IGF-1 DES?
This modified growth factor emerged from research into why some IGF-1 variants show dramatically different potency despite similar receptor binding. By removing just three amino acids from the N-terminus, researchers created a peptide that delivers roughly 10-fold greater biological activity than standard IGF-1. Muscle physiology and tissue repair laboratories frequently investigate this variant for its ability to promote localized growth effects.
The key lies in binding proteins that normally sequester IGF-1 in circulation—IGF-1 DES largely sidesteps these molecular chaperones due to its truncated structure. While it still activates IGF-1 receptors with full strength, much more of the peptide remains unbound and biologically active in tissues. Think of it as removing the safety locks that normally keep IGF-1 activity in check.
What the Research Shows
Six studies total—all conducted in cell culture or animal models with no progression to human trials despite clear proof-of-concept data.
Notable Studies
Kaplan-Lefko PJ, Sutherland BW, Evangelou AI et al. · Oncogene (2008)
Animal
Hill DJ, Sedran RJ, Brenner SL et al. · J Endocrinol (1997)
Animal
Guan J, Williams CE, Skinner SJ et al. · Endocrinology (1996)
Animal
McGrath MF, Collier RJ, Clemmons DR et al. · Endocrinology (1991)
In Vitro
Bagley CJ, May BL, Szabo L et al. · Biochem J (1989)
In Vitro
Reported Benefits
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.